[go: up one dir, main page]

BRPI0907463A2 - forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias - Google Patents

forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias

Info

Publication number
BRPI0907463A2
BRPI0907463A2 BRPI0907463A BRPI0907463A BRPI0907463A2 BR PI0907463 A2 BRPI0907463 A2 BR PI0907463A2 BR PI0907463 A BRPI0907463 A BR PI0907463A BR PI0907463 A BRPI0907463 A BR PI0907463A BR PI0907463 A2 BRPI0907463 A2 BR PI0907463A2
Authority
BR
Brazil
Prior art keywords
triazole
inflammatory diseases
polymorphic form
treating inflammatory
pyridine derivative
Prior art date
Application number
BRPI0907463A
Other languages
English (en)
Inventor
John Butcher Kennneth
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of BRPI0907463A2 publication Critical patent/BRPI0907463A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
BRPI0907463A 2008-02-04 2009-01-28 forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias BRPI0907463A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2587908P 2008-02-04 2008-02-04
PCT/IB2009/050351 WO2009098612A2 (en) 2008-02-04 2009-01-28 Polymorphic form of a [1, 2, 4] triazolo [4, 3-a] pyridine derivative for treating inflammatory diseases

Publications (1)

Publication Number Publication Date
BRPI0907463A2 true BRPI0907463A2 (pt) 2019-09-24

Family

ID=40911989

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0907463A BRPI0907463A2 (pt) 2008-02-04 2009-01-28 forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias

Country Status (22)

Country Link
US (1) US8222273B2 (pt)
EP (1) EP2303267B1 (pt)
JP (1) JP5344942B2 (pt)
KR (2) KR101422318B1 (pt)
CN (1) CN101939320B (pt)
AR (1) AR070411A1 (pt)
AU (1) AU2009211072B2 (pt)
BR (1) BRPI0907463A2 (pt)
CA (1) CA2712574C (pt)
CY (1) CY1114389T1 (pt)
DK (1) DK2303267T3 (pt)
ES (1) ES2423991T3 (pt)
IL (1) IL206948A (pt)
MX (1) MX2010008535A (pt)
NZ (1) NZ587094A (pt)
PL (1) PL2303267T3 (pt)
PT (1) PT2303267E (pt)
RU (1) RU2448966C1 (pt)
SI (1) SI2303267T1 (pt)
TW (1) TWI391391B (pt)
WO (1) WO2009098612A2 (pt)
ZA (1) ZA201005137B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905955D0 (en) 2009-04-06 2009-05-20 Respivert Ltd Novel compounds
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
ES2710537T3 (es) 2010-09-29 2019-04-25 Pulmatrix Operating Co Inc Polvos secos catiónicos
US20140336159A1 (en) 2011-10-07 2014-11-13 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
CN105693716A (zh) * 2016-03-01 2016-06-22 孙霖 晶型a及制备方法
CN105646484A (zh) * 2016-03-01 2016-06-08 孙霖 晶型b及制备方法
GB201611712D0 (en) 2016-07-02 2016-08-17 Hvivo Services Ltd Methods and compounds for the treatment or prevention of severe or persistent influenza
GB201721793D0 (en) 2017-12-22 2018-02-07 Hvivo Services Ltd Methods and compunds for the treatment or prevention of hypercytokinemia and severe influenza

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990182A2 (en) 1998-06-11 2000-02-29 Du Pont Pharm Co Crystalline efavirenz
KR100652326B1 (ko) 1998-11-20 2006-11-29 미쯔비시 가가꾸 가부시끼가이샤 5-[(6-(2-플루오로벤질)옥시-2-나프틸)메틸]-2,4-티아졸리딘디온의 결정체
WO2006008752A1 (en) 2004-07-16 2006-01-26 Usv Limited Novel polymorphs of atovaquone and process of preparation thereof
DE602005010714D1 (de) * 2004-08-12 2008-12-11 Pfizer Der p38-map-kinase
GB0418015D0 (en) * 2004-08-12 2004-09-15 Pfizer Ltd New compounds

Also Published As

Publication number Publication date
US8222273B2 (en) 2012-07-17
HK1147481A1 (zh) 2011-08-12
EP2303267B1 (en) 2013-07-03
SI2303267T1 (sl) 2013-09-30
CY1114389T1 (el) 2016-08-31
PL2303267T3 (pl) 2013-11-29
AU2009211072B2 (en) 2014-01-23
RU2448966C1 (ru) 2012-04-27
PT2303267E (pt) 2013-08-05
WO2009098612A3 (en) 2009-10-08
TW200944524A (en) 2009-11-01
KR20100108409A (ko) 2010-10-06
RU2010132639A (ru) 2012-02-10
NZ587094A (en) 2011-07-29
AU2009211072A1 (en) 2009-08-13
JP5344942B2 (ja) 2013-11-20
IL206948A0 (en) 2010-12-30
JP2009185028A (ja) 2009-08-20
KR20130087048A (ko) 2013-08-05
IL206948A (en) 2014-12-31
CA2712574A1 (en) 2009-08-13
DK2303267T3 (da) 2013-09-02
MX2010008535A (es) 2010-08-30
US20110003848A1 (en) 2011-01-06
AR070411A1 (es) 2010-04-07
WO2009098612A2 (en) 2009-08-13
EP2303267A2 (en) 2011-04-06
ES2423991T3 (es) 2013-09-26
TWI391391B (zh) 2013-04-01
CN101939320A (zh) 2011-01-05
CN101939320B (zh) 2013-11-20
KR101422318B1 (ko) 2014-07-22
ZA201005137B (en) 2011-03-30
CA2712574C (en) 2014-01-07

Similar Documents

Publication Publication Date Title
BRPI0907463A2 (pt) forma polimórfica de um derivado de [1,2,4] triazol [4,3-a] piridina para tratamento de doenças inflamatórias
BRPI0909541A2 (pt) ''método para tratamento de doenças inflamatórias do cólon''
AP2010005508A0 (en) Triazole derivatives useful for the treatment of diseases.
PL2321295T3 (pl) Pochodne 4-(pirydyn-4-ylo)-1H-[1,3,5]triazyn -2-onu jako inhibitory GSK2-beta do leczenia chorób degeneracyjnych
IL192150A0 (en) Therapeutic agent for inflammatory bowel disease containing as active ingredient 2-amino-1,3-propanediol derivative, or method for treating inflammatory bowel disease
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
BRPI0914555A2 (pt) derivados de triazol bicíclicos para o tratamento de tumores
EP1988083A4 (en) triazole
ZA201100032B (en) Triazole derivative or salt thereof
BRPI0811103A2 (pt) Compostos triazol para tratamento de formação de biopelícula
IL205102A0 (en) 1,3,5 - trisubstituted triazole derivative
IL206391A0 (en) Method for manufacturing heterocycle-substituted pyridine derivatives
DK1993589T3 (da) Behandlinger for neurologiske sygdomme
ZA200905700B (en) Triazole derivative as an HSP 90 inhibitor
SI2121553T1 (sl) Postopek za pripravo terapevtsko uporabnih trifenilbutenskih derivatov
BRPI0821357A2 (pt) derivados de oxadiazois de triazol
IL200091A (en) Kittensan to treat infectious diseases of the nail
GB0700972D0 (en) Treatment of inflammatory disease
GB0720976D0 (en) Treatment of inflammatory disease
FI20070455A0 (fi) Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon
EP1981343A4 (en) TREATMENT OF INFLAMMATORY DISEASES WITH TRIAZOL COMPOUNDS
IL209947A (en) Compounds for the treatment of corneal inflammation
BRPI1009145A2 (pt) método para a fabricação de derivado de benzodiazepina
ZA200707592B (en) Novel compounds for treating inflammatory diseases
EP2216337A4 (en) METHOD FOR PRODUCING A 4-DESOXY-4-FLUOR-D-GLUCOSE DERIVATIVE

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.